It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Dyne Therapeutics Inc (DYN) USD0.0001

Sell:$21.34 Buy:$21.48 Change: $0.09 (0.42%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
Change: $0.09 (0.42%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
Change: $0.09 (0.42%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dyne Therapeutics Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases. The Company’s FORCE platform therapeutics consists of an oligonucleotide payload that it designs to target the genetic basis of the disease. With its FORCE platform, the Company has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that it attaches to its Fab using the linker. Its DM1 program is focused on the development of a potentially disease-modifying treatment for DM1.

Contact details

830 Winter Street
United States
+1 (781) 7868230

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.08 billion
Shares in issue:
51.21 million
United States
US dollar

Key personnel

  • Jason Rhodes
    Chairman of the Board
  • Joshua Brumm
    President, Chief Executive Officer, Director
  • Susanna High
    Chief Operating Officer
  • Ashish Dugar
    Senior Vice President - Global head of Medical Affairs
  • Oxana Beskrovnaya
    Chief Scientific Officer
  • Richard Scalzo
    Vice President of Accounting and Administration, Treasurer
  • Jonathan McNeill
    Vice President, Business Development
  • Wildon Farwell
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.